<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F732250B-1EB7-4E99-8CDE-04DEB18630B5"><gtr:id>F732250B-1EB7-4E99-8CDE-04DEB18630B5</gtr:id><gtr:name>Victor Segalen Bordeaux 2 University</gtr:name><gtr:address><gtr:line1>Universite Victor Segalen Bordeaux 2</gtr:line1><gtr:line2>146 rue Leo Saignat</gtr:line2><gtr:line4>Bordeaux</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>33076</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Social Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F732250B-1EB7-4E99-8CDE-04DEB18630B5"><gtr:id>F732250B-1EB7-4E99-8CDE-04DEB18630B5</gtr:id><gtr:name>Victor Segalen Bordeaux 2 University</gtr:name><gtr:address><gtr:line1>Universite Victor Segalen Bordeaux 2</gtr:line1><gtr:line2>146 rue Leo Saignat</gtr:line2><gtr:line4>Bordeaux</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>33076</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A7F1755C-E942-4737-9C36-9C9977371DB5"><gtr:id>A7F1755C-E942-4737-9C36-9C9977371DB5</gtr:id><gtr:firstName>Bruno</gtr:firstName><gtr:surname>Ledergerber</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3D1BE2EA-694D-41BA-8055-D1DB7D3D3658"><gtr:id>3D1BE2EA-694D-41BA-8055-D1DB7D3D3658</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Nicholas</gtr:otherNames><gtr:surname>Phillips</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/62A5B14F-156F-4F9E-980D-75EDE4EA15FD"><gtr:id>62A5B14F-156F-4F9E-980D-75EDE4EA15FD</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>May</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3D63A384-98EE-4C63-B7FF-A182D68F700A"><gtr:id>3D63A384-98EE-4C63-B7FF-A182D68F700A</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Sterne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/65A15A0B-975F-4A60-BAFC-09378465160B"><gtr:id>65A15A0B-975F-4A60-BAFC-09378465160B</gtr:id><gtr:firstName>Matthias</gtr:firstName><gtr:surname>Egger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/86B121B0-A012-4AFB-A7F1-DDF7B2FFF656"><gtr:id>86B121B0-A012-4AFB-A7F1-DDF7B2FFF656</gtr:id><gtr:firstName>Jens</gtr:firstName><gtr:surname>Lundgren</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0100221"><gtr:id>0F7A9DBB-160E-47C9-977D-FEDE50A89CA5</gtr:id><gtr:title>Monitoring and modelling prognosis in the era of HAART (Extension to Strategic Grant G0100221)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100221</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>397948</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen (K?benhavns Universitet UCPH)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>4E69B8D0-5291-4840-9333-8D069E33B1B7</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>IeDEA Southern Africa</gtr:description><gtr:id>3406C513-BF7C-4561-A359-6E8A02AC7461</gtr:id><gtr:impact>publications as listed.</gtr:impact><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Prognostic modelling for pediatric HIV patients and comparative prognosis for adults comparing mortality with Europe and North America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Social and Preventive Medicine</gtr:department><gtr:description>ART-LINC</gtr:description><gtr:id>3E029D17-369A-41D7-9D50-75E107A76BA4</gtr:id><gtr:impact>Publication of 7 papers with authors funded by this grant or next grant. 17990236 19142294 18981768 18670668 18373510 18240981 16530575</gtr:impact><gtr:partnerContribution>Knowledge of HIV in low income countries.</gtr:partnerContribution><gtr:piContribution>Professors Matthias Egger and Francois Dabis established this sister collaboration based on HIV clinic cohorts in developing countreis. Sterne and May provided statistical support. We shared data for a study comparing outcomes in high and low income settings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux Segalen</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERN (1053) (Universit? Bordeaux Segalen)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>432835D7-05AF-4F50-9F26-D9D9DC8F8CAF</gtr:id><gtr:impact>2 papers published 19531926 ?</gtr:impact><gtr:partnerContribution>Knowledge of Non-hodgkins lymphoma in HIV infected persons</gtr:partnerContribution><gtr:piContribution>Sterne was involved in negotiations establishing this collaboration of European HIV cohort studies and is a member of the steering committee. Egger raised funds for and led work on non-Hodgkins lymphoma. May provided statistical advice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CNICS</gtr:description><gtr:id>6DF80CE6-E121-496A-9890-FE3FE0C5DEDB</gtr:id><gtr:impact>dataset</gtr:impact><gtr:partnerContribution>Data contributed to opportunistic infection modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux Segalen</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERN (1053) (Universit? Bordeaux Segalen)</gtr:department><gtr:description>ART-LINC</gtr:description><gtr:id>86496E3C-F691-4A2C-84F4-ECA333A562B5</gtr:id><gtr:impact>Publication of 7 papers with authors funded by this grant or next grant. 17990236 19142294 18981768 18670668 18373510 18240981 16530575</gtr:impact><gtr:partnerContribution>Knowledge of HIV in low income countries.</gtr:partnerContribution><gtr:piContribution>Professors Matthias Egger and Francois Dabis established this sister collaboration based on HIV clinic cohorts in developing countreis. Sterne and May provided statistical support. We shared data for a study comparing outcomes in high and low income settings.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux Segalen</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERN (1053) (Universit? Bordeaux Segalen)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>C98FC7DB-7A72-4927-9F7C-202934D3D007</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard School of Public Health</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>HIV-CAUSAL</gtr:description><gtr:id>ACC42F75-ECFB-4FA2-930E-06A1CA16A14A</gtr:id><gtr:impact>Paper of effect of ART.</gtr:impact><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>COHERE</gtr:description><gtr:id>6E07A2BD-A757-49A3-A74A-527FF1C21301</gtr:id><gtr:impact>2 papers published 19531926 ?</gtr:impact><gtr:partnerContribution>Knowledge of Non-hodgkins lymphoma in HIV infected persons</gtr:partnerContribution><gtr:piContribution>Sterne was involved in negotiations establishing this collaboration of European HIV cohort studies and is a member of the steering committee. Egger raised funds for and led work on non-Hodgkins lymphoma. May provided statistical advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:collaboratingOrganisation><gtr:country>Central African Republic</gtr:country><gtr:department>IeDEA West Africa Region</gtr:department><gtr:description>IeDEA West Africa</gtr:description><gtr:id>5B58108C-C5C0-4FDD-B5BD-8BFC99053B8F</gtr:id><gtr:impact>Paper in Press</gtr:impact><gtr:partnerContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:partnerContribution><gtr:piContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>IeDEA Southern Africa</gtr:description><gtr:id>29D4982C-4D57-4226-B4DB-167DEF65E24D</gtr:id><gtr:impact>publications as listed.</gtr:impact><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Prognostic modelling for pediatric HIV patients and comparative prognosis for adults comparing mortality with Europe and North America.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference on Retroviruses and Opportunistic Infections</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>666D29ED-4EE9-4329-9C79-D38960869B0B</gtr:id><gtr:impact>Attended the Conference on Retroviruses and Opportunistic Infections every year to present work, support team members and lead the ART-CC collaboration in its work on HIV-1 patients. This is a major, international conference with an audience of around 4,000 researchers in the field of opportunistic infections and retroviruses.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.croiconference.org/</gtr:url><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media appearances</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1C116050-20A2-4429-92F7-787AFD6B1A4B</gtr:id><gtr:impact>Television and radio appearances by Sterne, describing improved life expectancy of HIV-infected individuals, following publication of article in the Lancet (18657708)

Wider knowledge of the benefits of antiretroviral therapy</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BF7F93D6-6E0D-46D1-B217-2130424ECB55</gtr:id><gtr:impact>Appeared at a press conference during the 2009 Conference on Retrovirus and Opportunistic Infections, to describe work examining when HIV-infected individuals should start antiretroviral therapy

Coverage on several web sites providing information to HIV infected patients</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (G0700820)</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B5549DD7-4403-430A-A5CB-73117EE988E0</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>US HIV treatment guidelines</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel</gtr:guidelineTitle><gtr:id>14AE2E1D-C50C-4BB8-A3A4-077671EC707B</gtr:id><gtr:impact>Our work was cited in US guidelines on treatment of HIV-infected individuals</gtr:impact><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DHHS Panel on Antiretroviral Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents</gtr:guidelineTitle><gtr:id>BB7464B3-E37C-4113-B0C0-986DF65C9175</gtr:id><gtr:impact>The most recent US guidelines on antiretroviral therapy for HIV-infected individuals cite papers from the ART Cohort Collaboration, including and extensive discussion of our 2009 Lancet paper on timing of antiretroviral therapy (19361855) and our 2007 paper on 5 year prognosis (17502729)</gtr:impact><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Our website at www.art-cohort-collaboration.org provides a prognostic model for use by patients and their carers.</gtr:description><gtr:id>BE79DCC6-91A0-457E-97FC-99F2ACAF3FE3</gtr:id><gtr:impact>The web site has been accessed tens of thousands of times</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prognostic model</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.art-cohort-collaboration.org</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/761DBEF5-E17D-4EB1-BC68-A0DAD6343D56"><gtr:id>761DBEF5-E17D-4EB1-BC68-A0DAD6343D56</gtr:id><gtr:title>Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ee2bab53379aeb12dd7a47feb47a0b6"><gtr:id>6ee2bab53379aeb12dd7a47feb47a0b6</gtr:id><gtr:otherNames>Braitstein P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/178FC1AA-432A-4E02-8C89-197B9A932648"><gtr:id>178FC1AA-432A-4E02-8C89-197B9A932648</gtr:id><gtr:title>Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/153E7C5D-98E0-48B2-9002-8F97AF9B6276"><gtr:id>153E7C5D-98E0-48B2-9002-8F97AF9B6276</gtr:id><gtr:title>Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1EE8100A-5055-4EC5-A9BA-25B70C14399E"><gtr:id>1EE8100A-5055-4EC5-A9BA-25B70C14399E</gtr:id><gtr:title>Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9E9678F-6A36-430E-94B3-8ED72B116F8E"><gtr:id>C9E9678F-6A36-430E-94B3-8ED72B116F8E</gtr:id><gtr:title>Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d1efdda13511cb84b95a40a6f093861"><gtr:id>8d1efdda13511cb84b95a40a6f093861</gtr:id><gtr:otherNames>Abgrall, S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5498F002-3DA1-4417-96DB-5919E7D09384"><gtr:id>5498F002-3DA1-4417-96DB-5919E7D09384</gtr:id><gtr:title>A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37146F67-0B2A-4E01-B32A-98C0DFADB5E6"><gtr:id>37146F67-0B2A-4E01-B32A-98C0DFADB5E6</gtr:id><gtr:title>The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A57C2D69-C43D-4098-B2DB-93E6B5180C37"><gtr:id>A57C2D69-C43D-4098-B2DB-93E6B5180C37</gtr:id><gtr:title>The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy (Vol 165, pg 416, 2005)</gtr:title><gtr:parentPublicationTitle>ARCHIVES OF INTERNAL MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bf231e5d82dcd028807c693b19f30759"><gtr:id>bf231e5d82dcd028807c693b19f30759</gtr:id><gtr:otherNames>Monforte AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0003-9926</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C19AF1A3-A77F-4206-A352-10BC516B2FC0"><gtr:id>C19AF1A3-A77F-4206-A352-10BC516B2FC0</gtr:id><gtr:title>Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0766DD4-4F73-4DA2-9312-6C49E94F2BA1"><gtr:id>C0766DD4-4F73-4DA2-9312-6C49E94F2BA1</gtr:id><gtr:title>Immunodeficiency at the start of ART: Global view</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82a9a381de2ab654051026a00cf70fe8"><gtr:id>82a9a381de2ab654051026a00cf70fe8</gtr:id><gtr:otherNames>Mugglin, C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEEA0DE0-0D65-42C7-B419-5A357408E3F4"><gtr:id>DEEA0DE0-0D65-42C7-B419-5A357408E3F4</gtr:id><gtr:title>Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies</gtr:title><gtr:parentPublicationTitle>ANTIVIRAL THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19c011085070b312df0ca2919931e55b"><gtr:id>19c011085070b312df0ca2919931e55b</gtr:id><gtr:otherNames>Harris Ross J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7066E5B-7A94-491F-A721-80010D2809E5"><gtr:id>E7066E5B-7A94-491F-A721-80010D2809E5</gtr:id><gtr:title>Prognosis of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: A Collaborative Analysis of Scale-up Programs</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/daf40f9d812f3b78a8fa25bea666f0f6"><gtr:id>daf40f9d812f3b78a8fa25bea666f0f6</gtr:id><gtr:otherNames>May, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9033F6C-BC6C-4328-BD09-E7D50A9CEEF8"><gtr:id>F9033F6C-BC6C-4328-BD09-E7D50A9CEEF8</gtr:id><gtr:title>Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy - Collaborative analysis of cohorts of HIV-1-Infected patients</gtr:title><gtr:parentPublicationTitle>JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ad92815ac594ac380e840d00e9d6c3b"><gtr:id>8ad92815ac594ac380e840d00e9d6c3b</gtr:id><gtr:otherNames>Sterne Jonathan A. C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB84EC20-3A06-4CF0-A90B-1E15073EFEC3"><gtr:id>BB84EC20-3A06-4CF0-A90B-1E15073EFEC3</gtr:id><gtr:title>Outcomes of Abacavir and Efavirenz based HAART: Comparison of ACTG 5095 Trial Results with Observational Cohort Studies</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b5f0dcef4396fbf5bc3b6b0e7388179c"><gtr:id>b5f0dcef4396fbf5bc3b6b0e7388179c</gtr:id><gtr:otherNames>Mugavero, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CEFEA343-A530-4BFC-9DD8-E8FFAA6EA2D3"><gtr:id>CEFEA343-A530-4BFC-9DD8-E8FFAA6EA2D3</gtr:id><gtr:title>Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4340bf573d969d184a2766e9bd75327b"><gtr:id>4340bf573d969d184a2766e9bd75327b</gtr:id><gtr:otherNames>Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/250CE521-08CB-4E9B-B2E4-25065B485AE3"><gtr:id>250CE521-08CB-4E9B-B2E4-25065B485AE3</gtr:id><gtr:title>Causal inference for dynamic treatment regimens: how analyses of observational data changed international guidelines on when to start antiretroviral therapy.</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/581f630b37a454fc3bd2fbf6859753a4"><gtr:id>581f630b37a454fc3bd2fbf6859753a4</gtr:id><gtr:otherNames>STERNE J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCD003EA-5855-427F-9A9B-09EBA6D7BD8D"><gtr:id>FCD003EA-5855-427F-9A9B-09EBA6D7BD8D</gtr:id><gtr:title>When to Start ART</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7ddcd487f09db4186cd29b6c9a89a65"><gtr:id>a7ddcd487f09db4186cd29b6c9a89a65</gtr:id><gtr:otherNames>STERNE, J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5F4747FE-DC93-4A77-839E-9DDD71DBEB93"><gtr:id>5F4747FE-DC93-4A77-839E-9DDD71DBEB93</gtr:id><gtr:title>Determinants of Waiting Times for ART in the Free State Province, South Africa</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db2417bd1e9824844bae1de5235a57c6"><gtr:id>db2417bd1e9824844bae1de5235a57c6</gtr:id><gtr:otherNames>Ingle, S.M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A73A2792-CC43-4EB9-8E4D-7A69D10DD23B"><gtr:id>A73A2792-CC43-4EB9-8E4D-7A69D10DD23B</gtr:id><gtr:title>Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9263D729-1ABF-4360-A5CE-E376DCC3F37C"><gtr:id>9263D729-1ABF-4360-A5CE-E376DCC3F37C</gtr:id><gtr:title>Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4fbf3c9de6cb390e73a7d1bfa25f1283"><gtr:id>4fbf3c9de6cb390e73a7d1bfa25f1283</gtr:id><gtr:otherNames>Harris RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6C4D006-DA80-4669-B6B3-718B0082263F"><gtr:id>E6C4D006-DA80-4669-B6B3-718B0082263F</gtr:id><gtr:title>HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da567e0749728cb450f3e0581d24435d"><gtr:id>da567e0749728cb450f3e0581d24435d</gtr:id><gtr:otherNames>Sterne JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/584658BC-D99F-4669-B7D1-8F5C9C7D5E6C"><gtr:id>584658BC-D99F-4669-B7D1-8F5C9C7D5E6C</gtr:id><gtr:title>Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/38d39f647b004bf7657a378a8ddceb5e"><gtr:id>38d39f647b004bf7657a378a8ddceb5e</gtr:id><gtr:otherNames>Sterne JAC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C1D37DC2-F853-4A7E-BB83-3254D4A2AD2A"><gtr:id>C1D37DC2-F853-4A7E-BB83-3254D4A2AD2A</gtr:id><gtr:title>Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America</gtr:title><gtr:parentPublicationTitle>CLINICAL INFECTIOUS DISEASES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d5af412447d4cb7cd648c22233832e5"><gtr:id>0d5af412447d4cb7cd648c22233832e5</gtr:id><gtr:otherNames>Costagliola D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B0364CE-BA54-4FB7-A951-65B15B68564C"><gtr:id>9B0364CE-BA54-4FB7-A951-65B15B68564C</gtr:id><gtr:title>When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7372a0a0e63d31deab6b40a83d243c44"><gtr:id>7372a0a0e63d31deab6b40a83d243c44</gtr:id><gtr:otherNames>HIV-CAUSAL Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5EA59B32-1EF9-4CC7-9A05-0B75B5C850FD"><gtr:id>5EA59B32-1EF9-4CC7-9A05-0B75B5C850FD</gtr:id><gtr:title>Causal inference for dynamic treatment regimens: how analyses of observational data changed international guidelines on when to start antiretroviral therapy,</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7ddcd487f09db4186cd29b6c9a89a65"><gtr:id>a7ddcd487f09db4186cd29b6c9a89a65</gtr:id><gtr:otherNames>STERNE, J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/86E199FF-28CF-4722-8F2D-47C7FE9BCCEF"><gtr:id>86E199FF-28CF-4722-8F2D-47C7FE9BCCEF</gtr:id><gtr:title>Rates of disease progression according to initial highly active antiretroviral therapy regimen: A collaborative analysis of 12 prospective cohort studies</gtr:title><gtr:parentPublicationTitle>JOURNAL OF INFECTIOUS DISEASES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a72b47a6d91bdbb5f006f3890ce0cd69"><gtr:id>a72b47a6d91bdbb5f006f3890ce0cd69</gtr:id><gtr:otherNames>Egger Matthias</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90C1EE77-D90E-4D01-BD48-BB4881634A89"><gtr:id>90C1EE77-D90E-4D01-BD48-BB4881634A89</gtr:id><gtr:title>A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/452EEDBC-139A-4032-A4DE-0396DC932662"><gtr:id>452EEDBC-139A-4032-A4DE-0396DC932662</gtr:id><gtr:title>Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ee2bab53379aeb12dd7a47feb47a0b6"><gtr:id>6ee2bab53379aeb12dd7a47feb47a0b6</gtr:id><gtr:otherNames>Braitstein P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/042E0480-F391-4B16-B41D-989502D04D81"><gtr:id>042E0480-F391-4B16-B41D-989502D04D81</gtr:id><gtr:title>Pre-treatment Mortality and Probability of Starting ART in Patients Enrolled in the Free State ARV Program, South Africa: Implications for Treatment Guidelines</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db2417bd1e9824844bae1de5235a57c6"><gtr:id>db2417bd1e9824844bae1de5235a57c6</gtr:id><gtr:otherNames>Ingle, S.M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D39C2079-41BF-47BA-8292-8534714103EA"><gtr:id>D39C2079-41BF-47BA-8292-8534714103EA</gtr:id><gtr:title>HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B509A770-30EF-40F3-B306-EDEA4506A8A9"><gtr:id>B509A770-30EF-40F3-B306-EDEA4506A8A9</gtr:id><gtr:title>Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4636179c9d21cbc8d884847bab3c4050"><gtr:id>4636179c9d21cbc8d884847bab3c4050</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAE30C1C-79DB-4C00-840E-3B900F3CC682"><gtr:id>AAE30C1C-79DB-4C00-840E-3B900F3CC682</gtr:id><gtr:title>Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98eb151f9eb3ad3e80094a0d78d5a403"><gtr:id>98eb151f9eb3ad3e80094a0d78d5a403</gtr:id><gtr:otherNames>Chene G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6128492-6196-4D36-ACFA-4649D81D3F24"><gtr:id>E6128492-6196-4D36-ACFA-4649D81D3F24</gtr:id><gtr:title>Mortality of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: The IeDEA Prognostic Model</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/daf40f9d812f3b78a8fa25bea666f0f6"><gtr:id>daf40f9d812f3b78a8fa25bea666f0f6</gtr:id><gtr:otherNames>May, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD7607E6-21D8-49DC-ADF1-C20CD35EE59D"><gtr:id>DD7607E6-21D8-49DC-ADF1-C20CD35EE59D</gtr:id><gtr:title>The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1397de97da907fda4b5d9b28f4e385dd"><gtr:id>1397de97da907fda4b5d9b28f4e385dd</gtr:id><gtr:otherNames>Kowalska JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5A0759C-2BC1-43E2-9A31-470D99459A2A"><gtr:id>F5A0759C-2BC1-43E2-9A31-470D99459A2A</gtr:id><gtr:title>Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b592133b6390380c2aee126b71e9bf81"><gtr:id>b592133b6390380c2aee126b71e9bf81</gtr:id><gtr:otherNames>May M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C9CE94B-2FC8-443B-A462-DC6E9BAE3E42"><gtr:id>3C9CE94B-2FC8-443B-A462-DC6E9BAE3E42</gtr:id><gtr:title>HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f159e1d9115c2a8bce7ad625acd62261"><gtr:id>f159e1d9115c2a8bce7ad625acd62261</gtr:id><gtr:otherNames>May Margaret T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2A6A81A1-81D3-43F2-BAA8-37DB400FD0AA"><gtr:id>2A6A81A1-81D3-43F2-BAA8-37DB400FD0AA</gtr:id><gtr:title>AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7349c0bd832958cf2bc66557a2f2de88"><gtr:id>7349c0bd832958cf2bc66557a2f2de88</gtr:id><gtr:otherNames>Sabine C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29C8F85B-8533-47ED-B092-252F0FB607A4"><gtr:id>29C8F85B-8533-47ED-B092-252F0FB607A4</gtr:id><gtr:title>How early to start: what do observational data suggest?</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cdac88a583371e15672a469c38473312"><gtr:id>cdac88a583371e15672a469c38473312</gtr:id><gtr:otherNames>Sterne J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21F61B6E-62E1-42BF-A5E4-A366E417D7F8"><gtr:id>21F61B6E-62E1-42BF-A5E4-A366E417D7F8</gtr:id><gtr:title>A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f17553136749cbc8bc12683568ea866"><gtr:id>3f17553136749cbc8bc12683568ea866</gtr:id><gtr:otherNames>Gran JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2AAF16D1-69A2-4A38-922C-419EB1118CB5"><gtr:id>2AAF16D1-69A2-4A38-922C-419EB1118CB5</gtr:id><gtr:title>Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies</gtr:title><gtr:parentPublicationTitle>LANCET</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a5ca0cb5a14bbeaa3acfba1a2216611"><gtr:id>9a5ca0cb5a14bbeaa3acfba1a2216611</gtr:id><gtr:otherNames>Egger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AF125B1-9C42-4509-B39D-9CA86C82357A"><gtr:id>5AF125B1-9C42-4509-B39D-9CA86C82357A</gtr:id><gtr:title>HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da567e0749728cb450f3e0581d24435d"><gtr:id>da567e0749728cb450f3e0581d24435d</gtr:id><gtr:otherNames>Sterne JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100221</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>